Advertisement
"MedImmune is committed to finding innovative solutions that may one dayhelp patients struggling with respiratory diseases," said Tony Coyle, vicepresident, head, autoimmunity inflammation and respiratory disease research."We are pleased to present a plethora of promising data that could potentiallyaddress diseases such as asthma and chronic obstructive pulmonary disease."
Advertisement
The preceding presentations will occur on Tuesday, May 20 from8:15 a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.
About MedImmune
MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) andis the worldwide biologics business for the AstraZeneca Group. The companyhas approximately 3,000 employees worldwide and is headquartered inGaithersburg, Maryland. MedImmune strives to provide better medicines topatients, new medical options for physicians and rewarding careers toemployees. Dedicated to advancing science and medicine to help people livebetter lives, the company is focused on infection, oncology, respiratorydisease and inflammation, cardiovascular/gastrointestinal disease andneuroscience. For more information, visit MedImmune's website atwww.medimmune.com.MedImmune research scheduled to be presented includes: -- Regulation of Lung Inflammation in Animal Models (Poster Session: IL-33, the Ligand for T1/ST2, Induces Airway Hyperresponsiveness Via a Mast Cell but Not T Cell Dependent Mechanism, publication page A63) - Sunday, May 18 from 8:15 a.m.- 4:15 p.m., Metro Toronto Convention Centre, Area E. -- Viral Infection and Wheezing (Poster Session: Evidence for T-Lymphocyte Independent Antibody Responses in Primary RSV Infection, publication page A190)-Sunday, May 18 from 8:15 a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area A. -- Chitins: Flying High (Symposium: Hyperresponsiveness and Inflammation in a Murine Model of Asthma, publication page A501)- Monday, May 19 at 2:45 p.m., Ontario, Fairmont Royal York Hotel. -- New Insights and Developing Controversies in Clinical Asthma (Poster Session: Safety Profile, Pharmacokinetics and Biologic Activity of a Single IV Dose of the Anti IL-5 Receptor Alpha Antibody MEDI-563 in Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from 8:15 a.m.- 11:00 a.m., Metro Toronto Convention Centre, Room 205A. -- Eosinophils, Mast Cells and Neutrophils as Modulators of Immunity and Injury -- Poster Session: In Vitro Characterization of MEDI-563, a Humanized Anti-IL-5Ralpha Monoclonal Antibody in Phase1 Clinical Trial, publication page A602 -- Poster Session: MEDI-563, a Humanized Anti-Human IL-5R alpha Antibody Binds to Lung Tissue Eosinophils in Asthmatic Patients, publication page A602 -- Poster Session: A Monoclonal Anti-IL-5 Receptor (IL-5R) alpha Antibody with Enhanced ADCC Selectively and Efficaciously Depletes Tissue Eosinophils in IL-5 Transgenic Mice, publication page A603
SOURCE MedImmune
